EA201991160A1 - MEANS OF COMBINED THERAPY OF ATHEROSCLEROSIS, INCLUDING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - Google Patents
MEANS OF COMBINED THERAPY OF ATHEROSCLEROSIS, INCLUDING ATHEROSCLEROTIC CARDIOVASCULAR DISEASEInfo
- Publication number
- EA201991160A1 EA201991160A1 EA201991160A EA201991160A EA201991160A1 EA 201991160 A1 EA201991160 A1 EA 201991160A1 EA 201991160 A EA201991160 A EA 201991160A EA 201991160 A EA201991160 A EA 201991160A EA 201991160 A1 EA201991160 A1 EA 201991160A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- atherosclerosis
- pcsk9
- cardiovascular disease
- combined therapy
- therapies
- Prior art date
Links
Abstract
В данном документе предусмотрены комбинации средств терапии, которые обеспечивают лечение, включая регрессию, атеросклероза и/или улучшение сердечно-сосудистых исходов. В общем описано, что это включает первое средство, не связанное с PCSK9, для снижения уровня LDL-C (такое как средство терапии, содержащее статин, или другое средство терапии, не связанное с PCSK9, для снижения уровня LDL-C) в сочетании со вторым средством терапии на основе ингибитора PCSK9 (таким как антитело или РНК к PCSK9). Было определено, что применение обоих средств терапии при достаточно повышенных уровнях, так чтобы обеспечить снижение уровня LDL-C у субъекта до очень низких уровней в течение достаточного периода времени, обеспечивает добавленное преимущество дополнительной защиты в отношении атеросклероза и улучшение сердечно-сосудистых исходов у субъекта.This document provides combinations of therapies that provide treatment, including regression, atherosclerosis, and / or improved cardiovascular outcomes. It is generally described that this includes a first non-PCSK9-related drug for lowering LDL-C (such as a statin-containing therapy or another non-PCSK9-related drug for lowering LDL-C) in combination with a second PCSK9 inhibitor-based therapy (such as an antibody or anti-PCSK9 RNA). It has been determined that the use of both therapies at sufficiently elevated levels, so as to ensure that the LDL-C level in the subject is reduced to very low levels for a sufficient period of time, provides the added benefit of additional protection against atherosclerosis and improved cardiovascular outcomes in the subject.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584600P | 2017-11-10 | 2017-11-10 | |
| PCT/US2017/061346 WO2018089912A2 (en) | 2016-11-14 | 2017-11-13 | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991160A1 true EA201991160A1 (en) | 2019-12-30 |
Family
ID=69061893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991160A EA201991160A1 (en) | 2017-11-10 | 2017-11-13 | MEANS OF COMBINED THERAPY OF ATHEROSCLEROSIS, INCLUDING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE |
Country Status (1)
| Country | Link |
|---|---|
| EA (1) | EA201991160A1 (en) |
-
2017
- 2017-11-13 EA EA201991160A patent/EA201991160A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201592304A1 (en) | METHODS OF TREATMENT OF AUTOSOME-DOMINANT HYPERSHOLESTERYNEMIA ASSOCIATED WITH THE MUTATION OF ACQUISITION OF PCSK9 GENE | |
| MX2021000898A (en) | METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH). | |
| PH12017501818A1 (en) | Fgfr/pd-1 combination therapy for the treatment of cancer | |
| MX2019008197A (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFß1 INHIBITORS AND USE THEREOF. | |
| EA201790195A1 (en) | METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS | |
| EA201790142A1 (en) | TREATMENT OF LEUKEMIA INHIBITORS HISTONDEACETYLASE | |
| MX2020004023A (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia. | |
| EA201592302A1 (en) | WAYS TO REDUCE THE LEVEL OF RESIDUAL CHOLESTEROL AND OTHER FRIPTIONS OF LIPOPROTEINS BY INTRODUCING PROTROTEIN CONVERTASE INHIBITOR SUBTILYSIN-KEXIN TYPE 9 (PCSK9) | |
| TN2019000156A1 (en) | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease | |
| MX2016010504A (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy. | |
| EA201101117A1 (en) | DPP-4 INHIBITORS FOR THE TREATMENT OF DIABETES IN CHILDREN | |
| EA201691683A1 (en) | ANTIBODIES AGAINST DLL3 AND CONJUGATES ANTIBODY AND MEDICINE FOR USE FOR MELANOMA | |
| BR112015023294A2 (en) | method for treating or preventing a disease | |
| PH12016502167A1 (en) | Hdl theraphy markers | |
| EA201200559A1 (en) | METHODS OF APPOINTMENT PYRPHENIDONE THERAPY | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| MA39963A (en) | Methods for treating inflammatory bowel disease | |
| MX2016006226A (en) | Dosing regimens for use with pcsk9 inhibitors. | |
| MX2017000628A (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia. | |
| BR112015026021A2 (en) | combination therapy comprising a tor kinase inhibitor and n- (3- (5-fluoro-2- (4- (2-methoxyethoxy) phenylamino) pyrimidin-4-ylamino) phenyl) acrylamide for cancer treatment | |
| MX2019004573A (en) | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction. | |
| EA201890519A1 (en) | INHIBITING ANTIBODIES AGAINST PCSK9 FOR THE TREATMENT OF PATIENTS WITH HYPERLIPIDEMIA EXPOSING TO LIPOPROTEIN SCARVA | |
| WO2018052891A3 (en) | Modulation of pcsk9 and ldlr through drp1 inhibition | |
| MA38488A1 (en) | Forms of (s) -quinuclidin-3-yl (2- (2- (4-fluorophenyl) thiazol-4-yl) propan-2-yl) carbamate salt | |
| EA201791933A1 (en) | INHIBITION OF OLIG2 ACTIVITY |